Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOTH Hoth Therapeutics	$1.28 -0.8%	$1.29	$0.60 ▼ $3.80	$16.97M	0.66	4.07 million shs	187,386 shs
INM InMed Pharmaceuticals	$2.32 -0.9%	$2.70	$1.72 ▼ $15.70	$4.64M	0.29	1.48 million shs	76,909 shs
PASG Passage Bio	$6.95 -8.4%	$7.10	$5.12 ▼ $26.60	$22.10M	1.81	27,935 shs	61,413 shs
SYBX Synlogic	$1.48 +2.1%	$1.36	$0.90 ▼ $1.96	$17.32M	0.52	26,912 shs	15,101 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOTH Hoth Therapeutics	-0.77%	+3.20%	-3.73%	+49.97%	+118.64%
INM InMed Pharmaceuticals	+4.00%	+4.46%	-15.83%	-20.68%	-21.11%
PASG Passage Bio	+18.97%	+34.22%	+27.56%	+25.66%	-49.37%
SYBX Synlogic	-3.33%	+6.55%	+9.85%	+34.26%	+2.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOTH Hoth Therapeutics	3.127 of 5 stars	3.6	5.0	3.0	0.0	0.6
INM InMed Pharmaceuticals	1.3516 of 5 stars	0.0	5.0	3.4	0.0	0.6
PASG Passage Bio	3.9132 of 5 stars	3.5	5.0	3.2	2.5	1.3
SYBX Synlogic	0.9606 of 5 stars	0.0	3.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOTH Hoth Therapeutics	3.25	Buy	$4.00	212.50% Upside
INM InMed Pharmaceuticals	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$91.75	1,220.14% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INM, HOTH, PASG, and SYBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
INM InMed Pharmaceuticals	$4.60M	1.01	N/A	N/A	$20.64 per share	0.11
PASG Passage Bio	N/A	N/A	N/A	N/A	$12.04 per share	N/A
SYBX Synlogic	$10K	1,731.60	N/A	N/A	$1.08 per share	1.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	N/A
INM InMed Pharmaceuticals	-$7.68M	-$12.09	N/A	∞	N/A	-168.87%	-107.93%	-82.97%	9/26/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$20.40	N/A	N/A	N/A	N/A	-103.87%	-59.95%	N/A
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	-8.09%	-5.50%	N/A

Latest INM, HOTH, PASG, and SYBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOTH Hoth Therapeutics	N/A	27.54	15.08
INM InMed Pharmaceuticals	0.06	3.49	3.04
PASG Passage Bio	N/A	3.05	3.74
SYBX Synlogic	N/A	3.63	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOTH Hoth Therapeutics	7.08%
INM InMed Pharmaceuticals	20.12%
PASG Passage Bio	53.48%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
HOTH Hoth Therapeutics	6.92%
INM InMed Pharmaceuticals	1.43%
PASG Passage Bio	5.00%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOTH Hoth Therapeutics	4	13.26 million	12.30 million	Not Optionable
INM InMed Pharmaceuticals	10	2.00 million	1.97 million	Not Optionable
PASG Passage Bio	130	3.18 million	2.96 million	Optionable
SYBX Synlogic	80	11.70 million	11.35 million	Optionable

INM, HOTH, PASG, and SYBX Headlines

Recent News About These Companies

Synlogic (SYBX) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INM, HOTH, PASG, and SYBX Company Descriptions

Hoth Therapeutics NASDAQ:HOTH

$1.28 -0.01 (-0.78%)

As of 04:00 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

InMed Pharmaceuticals NASDAQ:INM

$2.32 -0.02 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$2.31 -0.01 (-0.65%)

As of 04:29 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Passage Bio NASDAQ:PASG

$6.95 -0.64 (-8.43%)

Closing price 03:59 PM Eastern

Extended Trading

$7.00 +0.04 (+0.65%)

As of 04:31 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Synlogic NASDAQ:SYBX

$1.48 +0.03 (+2.07%)

As of 04:00 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time